West Pharmaceutical Services, Inc. (BVMF:W2ST34)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 106.26B |
| Revenue (ttm) | 16.80B |
| Net Income (ttm) | 2.83B |
| Shares Out | n/a |
| EPS (ttm) | 39.03 |
| PE Ratio | 37.53 |
| Forward PE | 34.34 |
| Dividend | 0.09 (0.21%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 17 |
| Average Volume | 119 |
| Open | 44.04 |
| Previous Close | 44.02 |
| Day's Range | 43.04 - 44.04 |
| 52-Week Range | 33.51 - 48.04 |
| Beta | 1.15 |
| RSI | 60.06 |
| Earnings Date | Apr 23, 2026 |
About BVMF:W2ST34
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, BVMF:W2ST34's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial numbers in USDNews
West to Participate in Upcoming Investor Conferences
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.
West Pharmaceutical Services Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and 47% higher adjusted EPS, driven by strong HVP component and biologics demand. Full-year guidance was raised for both revenue and EPS, with operational excellence and global regulatory trends supporting continued momentum.
West Pharma lifts 2026 profit forecast on strong demand for medical equipment
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include sy...
West Reports First-Quarter 2026 Results
Strong Start to the Year and Raising Full-Year Revenue and EPS guidance EXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, hig...
West to Host First-Quarter 2026 Conference Call
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will relea...
West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of it...
West Pharmaceutical Services Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong 2025 momentum sets up for 5%-7% growth in 2026, driven by high-value non-GLP-1 products and regulatory tailwinds like Annex 1. GLP-1 growth is conservatively guided, but both branded and generic segments show upside, supported by capacity expansion and robust market participation.
West Pharmaceutical Services Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership transition is underway with a strong executive team and external search. Growth is driven by biologics, biosimilars, and GLP-1s, with robust demand and capacity expansion. Margin improvement is expected from product mix and SmartDose divestiture, while regulatory changes and innovation support a long runway for high-value products.
West Pharma CEO Eric Green to retire after 11 years at the helm
West Pharmaceutical's chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11-year run at the helm.
Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.
EXTON, Pa., March 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positi...
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Feb. 27, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will prese...
West Announces Quarterly Dividend and Share Repurchase Program
EXTON, Pa., Feb. 17, 2026 /PRNewswire/ -- On February 16, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug ad...
West Pharmaceutical Services Earnings Call Transcript: Q4 2025
Delivered record 2025 results with over $3B in net sales, 8% adjusted EPS growth, and 70% higher free cash flow. 2026 guidance calls for 5%-7% organic revenue growth, double-digit EPS growth, and margin expansion, led by strong HVP component demand and ongoing capacity investments.
West Pharma forecasts 2026 profit above estimates on strong demand for drug components
West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on strong demand for its proprietary products, which include syringes and ...
West Reports Fourth-Quarter and Full-Year 2025 Results
– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Servi...
West Pharmaceutical Services Transcript: Status update
A fully integrated, design-verified prefillable syringe system streamlines development, regulatory submission, and supply chain management by consolidating all components and data from a single supplier. The system offers broad compatibility, robust quality controls, and milestone-based support, with future enhancements planned for sustainability.
West to Host Fourth-Quarter and Full-Year 2025 Conference Call
EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will relea...
Time To Buy The Dip In West Pharmaceutical Stock?
West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously b...
West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack
Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in inn...
West Pharmaceutical Services Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong growth in high-value product components, biologics, and GLP-1s is driving margin expansion and robust cash flow. Strategic divestitures and investments in capacity and innovation position the business for sustained 7%-9% organic growth and double-digit EPS gains.
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical ...
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company h...
West to Participate in Upcoming Investor Conference
EXTON, Pa. , Dec. 12, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Declares Quarterly Dividend
EXTON, Pa. , Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug ad...